Amyotrophic lateral sclerosis, better known as Lou Gehrig’s disease, is marked by the degeneration of motor neurons in the brain and spine. Beyond the sure signs of the disease that took the former New York Yankees player now also known as the namesake of ALS, however, little is known about its cause.
Now, a report in MIT Tech Review points to the possibility of treatment on the horizon. A drug made by French biotech Trophos aims to keep neurons in survival mode and away from degeneration mode.
Currently in clinical trials, the drug compound focuses specifically on nerve cell mitochondria and preventing any unhealthiness, dying off, or degeneration associated with it.
Posted by mlang
RSS Feeds
